Ipamorelin 5mg

4.9 stars

$45.00

Purchase this product now and earn 45 Points!
Category:

Size Options: 5mg Composition: Fragment 176-191 Form: Lyophilized Powder Purity: >99% Product Code: P-FRAG176-191

Enjoy Complimentary Shipping on Orders Over $200

Receive a Free 30ml Bac Water with Orders Over $200

Discounts Available for Larger Quantities

Description

Ipamorelin 5mg

Ipamorelin is a pentapeptide consisting of five amino acids and is classified as a ‘growth hormone secretagogue.’ While its precise mechanism of action is still being investigated by researchers, it is believed to function by binding to ghrelin receptors. Ipamorelin operates as a growth hormone secretagogue (GHS-R) with the potential to regulate energy levels and weight. This synthetic peptide shares similarities with natural growth hormones (HGH). Following numerous research studies and laboratory assessments, Ipamorelin has been identified as a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) capable of stimulating the pituitary gland and promoting the release of growth hormones.

Overview

Ipamorelin is groundbreaking as the first synthetic growth hormone secretagogue designed to boost the body’s production of natural growth hormone. This peptide exhibits a remarkable affinity for the growth receptors within the pituitary gland, akin to the receptor agonists of growth hormone-releasing peptides (GHRP). It has the potential to bind to GHRP receptors, potentially prompting an increase in growth hormone secretion.

Extensive research studies suggest that, unlike other hormones that stimulate HGH, Ipamorelin may not significantly elevate cortisol and Adrenocorticotropic (ACH) hormone levels in the bloodstream. Consequently, Ipamorelin stands out as a GHRP receptor agonist with a remarkable specificity for triggering growth hormone release, potentially without affecting ACH and cortisol levels.

Research and Clinical Studies

Ipamorelin Research and Early Findings

In 1998, a pivotal research study involving rats suggested that Ipamorelin could trigger the release of growth hormones from pituitary cells. This peptide, when administered to swine and anesthetized rats, was observed to elicit the release of growth hormones. Researchers speculated that Ipamorelin, similar to other growth hormone (GH)-stimulating peptides, might act as a growth receptor agonist, stimulating GH release by potentially binding to growth hormone receptors.

The following year, in 1999, additional research focused on adult female rats receiving Ipamorelin three times daily. After 15 days of administration, scientists not only noted an apparent increase in growth hormone levels but also observed an elevated longitudinal bone growth rate (LGR), which rose from 42 micrometers per day to as much as 52 micrometers per day.

Late in 1999, a clinical trial was conducted involving eight male subjects who received Ipamorelin every 15 minutes for a predetermined period. Two hours post-study, researchers reported a remarkable exponential increase in growth hormone levels, with the highest peak occurring within a single episode of Ipamorelin administration.

Ipamorelin and Its Role in Addressing Growth Deficiencies

Since 2001, numerous clinical studies have examined subjects with growth hormone deficiency. Growth hormone-releasing peptides have shown promise through two potential mechanisms: (i) stimulation of the pituitary gland to release growth hormones and (ii) action on the arcuate nucleus of the hypothalamus. Although these peptides, including Ipamorelin, have been reported to trigger significant growth hormone releases, it remains unclear which of the two mechanisms is primarily involved.

A study involving six subjects with growth hormone deficiency and associated growth failure spanned eight months, during which the subjects received graded concentrations of Ipamorelin. Researchers monitored episodic growth hormone secretion and toxicity levels every 12 hours throughout the study. After two months, they reported a substantial spike in growth hormone levels among the subjects, with little impact on GH levels observed in later stages of the trial.

CAS Number 
PubChem CID 
Molecular Weight 
  
Synonyms 
Storage (Lyophilized)

At 39 Fahrenheit: 2 years

At -4 Fahrenheit: 3 years

Ipamorelin 5mg

Ipamorelin is a pentapeptide consisting of five amino acids and is classified as a ‘growth hormone secretagogue.’ While its precise mechanism of action is still being investigated by researchers, it is believed to function by binding to ghrelin receptors. Ipamorelin operates as a growth hormone secretagogue (GHS-R) with the potential to regulate energy levels and weight. This synthetic peptide shares similarities with natural growth hormones (HGH). Following numerous research studies and laboratory assessments, Ipamorelin has been identified as a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) capable of stimulating the pituitary gland and promoting the release of growth hormones.

Overview

Ipamorelin is groundbreaking as the first synthetic growth hormone secretagogue designed to boost the body’s production of natural growth hormone. This peptide exhibits a remarkable affinity for the growth receptors within the pituitary gland, akin to the receptor agonists of growth hormone-releasing peptides (GHRP). It has the potential to bind to GHRP receptors, potentially prompting an increase in growth hormone secretion.

Extensive research studies suggest that, unlike other hormones that stimulate HGH, Ipamorelin may not significantly elevate cortisol and Adrenocorticotropic (ACH) hormone levels in the bloodstream. Consequently, Ipamorelin stands out as a GHRP receptor agonist with a remarkable specificity for triggering growth hormone release, potentially without affecting ACH and cortisol levels.

Research and Clinical Studies

Ipamorelin Research and Early Findings

In 1998, a pivotal research study involving rats suggested that Ipamorelin could trigger the release of growth hormones from pituitary cells. This peptide, when administered to swine and anesthetized rats, was observed to elicit the release of growth hormones. Researchers speculated that Ipamorelin, similar to other growth hormone (GH)-stimulating peptides, might act as a growth receptor agonist, stimulating GH release by potentially binding to growth hormone receptors.

The following year, in 1999, additional research focused on adult female rats receiving Ipamorelin three times daily. After 15 days of administration, scientists not only noted an apparent increase in growth hormone levels but also observed an elevated longitudinal bone growth rate (LGR), which rose from 42 micrometers per day to as much as 52 micrometers per day.

Late in 1999, a clinical trial was conducted involving eight male subjects who received Ipamorelin every 15 minutes for a predetermined period. Two hours post-study, researchers reported a remarkable exponential increase in growth hormone levels, with the highest peak occurring within a single episode of Ipamorelin administration.

Ipamorelin and Its Role in Addressing Growth Deficiencies

Since 2001, numerous clinical studies have examined subjects with growth hormone deficiency. Growth hormone-releasing peptides have shown promise through two potential mechanisms: (i) stimulation of the pituitary gland to release growth hormones and (ii) action on the arcuate nucleus of the hypothalamus. Although these peptides, including Ipamorelin, have been reported to trigger significant growth hormone releases, it remains unclear which of the two mechanisms is primarily involved.

A study involving six subjects with growth hormone deficiency and associated growth failure spanned eight months, during which the subjects received graded concentrations of Ipamorelin. Researchers monitored episodic growth hormone secretion and toxicity levels every 12 hours throughout the study. After two months, they reported a substantial spike in growth hormone levels among the subjects, with little impact on GH levels observed in later stages of the trial.

CAS Number
PubChem CID
Molecular Weight
Synonyms
Storage (Lyophilized) At 39 Fahrenheit: 2 years At -4 Fahrenheit: 3 years

Related products